注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
Revolution Medicines Inc是一家臨床階段精確腫瘤公司。該公司致力於開發靶向療法,以抑制臭名昭著的生長和生存途徑中難以捉摸的前沿靶點,特別強調腎素-血管緊張素系統(RAS)和雷帕黴素(mTOR)的哺乳動物靶點信號通路。該公司的研發(R&D)管道包括設計用於抑制多種RAS蛋白致癌變體的RAS(ON)抑製劑,以及用於聯合治療策略的RAS伴隨抑製劑。其正在研發的RAS(ON)抑製劑包括RMC-6236、RMC-6291、RMC-9805和RMC-8839,以及一系列針對其他RAS變體的研究化合物。臨床開發中的RAS伴隨抑製劑包括RMC-4630(SHP2)和RMC-5552(mTORC1/4EBP1)。該公司的三復合物技術能夠通過誘導新的藥物囊袋來發現缺乏內在藥物結合位點的靶點的小分子抑製劑。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Mark A. Goldsmith | 59 | 2014 | CEO, President & Chairman |
Kevan M. Shokat | - | 2016 | Academic Co-Founder & Member of Scientific Advisory Board |
Martin D. Burke | - | - | Co-Founder & Chairman of Scientific Advisory Board |
Michael A. Fischbach | 41 | 2016 | Academic Co-Founder & Member of Scientific Advisory Board |
Elizabeth McKee Anderson | 66 | 2015 | Independent Director |
Alexis A. Borisy | 51 | 2014 | Lead Independent Director |
Eric M. Gordon | - | 2016 | Senior Advisor & Member of Scientific Advisory Board |
John Kuriyan | - | 2016 | Senior Advisor & Member of Scientific Advisory Board |
Trever Bivona | - | 2016 | Senior Advisor & Member of Scientific Advisory Board |
Julian Adams | 68 | 2016 | Senior Advisor & Member of Scientific Advisory Board |
Barbara L. Weber | 66 | 2018 | Independent Director |
Flavia Borellini | 64 | 2021 | Independent Director |
Thilo Schroeder | 41 | 2018 | Independent Director |
Sue Gail Eckhardt | 65 | 2021 | Senior Advisor & Scientific Advisory Board Member |
Sushil Patel | 52 | 2022 | Independent Director |
Lorence H. Kim | 49 | 2022 | Independent Director |
Sandra J. Horning | 74 | 2023 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核